← The Wire
SNDXNasdaq
Syndax Pharmaceuticals Inc
Pharmaceutical Preparations · DE · CIK 1395937
Syndax Pharmaceuticals develops combination cancer therapies, including revumenib and axatilimab
red 8-K · 90d
$1.62B
Market cap
$21.78
Last close
+2.2%
1D
+12.7%
5D
4.7M
Volume
Price · last 39 sessions+9.1%
May 4L $16.96 · H $21.78Jun 29
227
Total filings
Jun 10, 2026
Last filing
12/31
Fiscal year end
S-1/AAMENDMENT NO. 4 TO FORM S-1Feb 26, 2016S-1/AAMENDMENT NO. 3 TO FORM S-1Feb 22, 2016S-1/AAMENDMENT NO. 2 TO FORM S-1Feb 10, 2016S-1/AAMENDMENT NO. 1 TO FORM S-1Jan 11, 2016S-1/AS-1/ANov 21, 2014S-1/AS-1/AAug 28, 2014S-1/AS-1/AJun 18, 2014S-1/AAMENDMENT NO. 2 TO FORM S-1Jun 5, 2014S-1/AS-1/AMay 16, 2014
Insider Activity
In the 90 days to Feb 9, 2026: 2 sold $628K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 9, 2026 | Metzger Michael AChief Executive Officer | Sell | 17,159 | $21.03 | $361K |
| Feb 9, 2026 | Goldan Keith A.Chief Financial Officer | Sell | 3,410 | $21.03 | $72K |
| Feb 6, 2026 | Metzger Michael AChief Executive Officer | Sell | 7,412 | $20.62 | $153K |
| Feb 6, 2026 | Goldan Keith A.Chief Financial Officer | Sell | 2,082 | $20.62 | $43K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance